Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Imidazenil, or a Combination of Imidazenil and [+]-Huperzine A and/or [-]-Huperzine A for Protection Against and/or Treatment of Seizure/Status Epilepticus and Neuropathology Following Nerve Agent or Organophosphate Exposure, Compositions and Kits, 2156-2157 [2014-00286]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
2156
Federal Register / Vol. 79, No. 8 / Monday, January 13, 2014 / Notices
professional corporation or professional
association; (2) provides services and
related supplies of a type rendered by
TRICARE individual professional
providers or diagnostic technical
services; (3) is approved for Medicare
payment or, when Medicare approval
status is not required, is accredited by
a qualified accreditation organization;
and (4) has entered into a participation
agreement approved by the Director,
DHA or a designee.
The collected information will be
used by TRICARE contractors to process
claims and verify authorized provider
status. Verification involves collecting
and reviewing copies of the provider’s
licenses, certificates, accreditation
documents, etc. If the criteria are met,
the provider is granted TRICARE
authorization status. The documentation
and information are collected when:
(1) A provider requests permission to
become a TRICARE-authorized
provider; (2) a claim is filed for care
received from a provider who is not
listed on the contractors’ computer
listing of authorized providers; or (3)
when a former TRICARE-authorized
provider requests reinstatement. The
contractors develop the forms used to
gather information based on TRICARE
conditions for participation listed
above. Without the collection of this
information, contractors cannot
determine if the provider meets
TRICARE-authorization requirements
for corporate services providers. If the
contractor is unable to verify that a
provider meets these authorization
requirements, the contractor may not
reimburse either the provider or the
beneficiary for the provider’s health care
services. To reduce the reporting burden
to a minimum, TRICARE has carefully
selected the information requested from
respondents. Only that information
which has been deemed absolutely
essential is being requested. If
necessary, contractors may verify
credentials with Medicare, JCAHO and
other national organizations by
telephone. TRICARE is also
participating with Medicare in the
development of a National Provider
System which will eliminate
duplication of provider certification
data collection among Federal
government agencies. TRICARE
contractors are required to maintain a
computer listing of all providers that
have submitted the appropriate
authorization information and
documentation. To avoid duplicate
inquires, the contractors must search the
computer provider listing before
requesting documentation from
providers. Since the providers affected
VerDate Mar<15>2010
16:40 Jan 10, 2014
Jkt 232001
by this information collection generally
have not previously been eligible to be
authorized providers, TRICARE
contractors will have no information on
file. The providers will have to submit
the information requested on the data
collection form (Application for
TRICARE-Providers Status: Corporate
Services Provider) in order to obtain
provider authorization status under
TRICARE. The information will usually
be collected from each respondent only
once. It is estimated that there will be
approximately 300 applicants per year.
TRICARE will request the provider
authorization documentation and
information when the provider asks to
become TRICARE-authorized or when a
claim is filed for a new provider’s
services. If after a provider has been
authorized by a contractor, no claims
are filed during two-year period of time,
the provider’s information will be
placed in the inactive file. To reactivate
a file, the provider must verify that the
information is still correct, or supply
new or changed information. The total
annual reporting burden is estimated to
be approximately 100 hours
(approximately 300 respondents with 20
minutes to complete the form).
Dated: January 7, 2014.
Aaron Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2014–00296 Filed 1–10–14; 8:45 am]
BILLING CODE 5001–06–P
Department of the Army
Notice of Availability for Exclusive,
Non-Exclusive, or Partially-Exclusive
Licensing of an Invention Concerning
Anti-Filovirus Therapeutics
Department of the Army, DoD.
Notice.
AGENCY:
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
761,942, entitled ‘‘Anti-Filovirus
Therapeutics,’’ filed on February 7,
2013. The United States Government, as
represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
SUMMARY:
PO 00000
Frm 00010
Fmt 4703
Sfmt 4703
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014–00290 Filed 1–10–14; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army
Notice of Availability for Exclusive,
Non-Exclusive, or Partially-Exclusive
Licensing of an Invention Concerning
Imidazenil, or a Combination of
Imidazenil and [+]-Huperzine A and/or
[-]-Huperzine A for Protection Against
and/or Treatment of Seizure/Status
Epilepticus and Neuropathology
Following Nerve Agent or
Organophosphate Exposure,
Compositions and Kits
Department of the Army, DoD.
ACTION: Notice.
AGENCY:
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
726,753, entitled ‘‘Imidazenil, or a
Combination of Imidazenil and [+]Huperzine A and/or [-]-Huperzine A for
Protection Against and/or Treatment of
Seizure/Status Epilepticus and
Neuropathology Following Nerve Agent
or Organophosphate Exposure,
Compositions and Kits,’’ filed on
November 15, 2012. The United States
Government, as represented by the
Secretary of the Army, has rights to this
invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
SUMMARY:
DEPARTMENT OF DEFENSE
ACTION:
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to an antisense
oligonucleotide directed to a mRNA
encoding a mammalian Niemann-Pick
C1 (NPC1) receptor, and combinations
thereof and compositions comprising
such are provided. Also provided are
methods of treating or reducing filovirus
infection of a subject.
For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\13JAN1.SGM
13JAN1
Federal Register / Vol. 79, No. 8 / Monday, January 13, 2014 / Notices
The
invention relates to methods,
compositions and kits for use in
protection against and/or treatment of
chemical warfare nerve agent (CWNA)
and/or organophosphate (OP) pesticide/
insecticide exposure. In particular, the
present invention relates to methods,
compositions and kits for treating,
preventing, inhibiting or reducing a
seizure, status epilepticus,
neuropathogenesis, or a neuropathology
caused by exposure to a CWNA or an
OP pesticide/insecticide using (a)
imidazenil, (b) a combination treatment
comprising imidazenil and [+]Huperzine A, (c) a combination
treatment comprising imidazenil and []-Huperzine A, or (d) a combination
treatment comprising imidazenil, [+]Huperzine A and [-]-Huperzine A.
SUPPLEMENTARY INFORMATION:
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014–00286 Filed 1–10–14; 8:45 am]
BILLING CODE 3710–08–P
Brenda S. Bowen,
Army Federal Register Liaison Officer.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
DEPARTMENT OF DEFENSE
AGENCY:
ACTION:
Department of the Army, DoD.
Notice.
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
851,599, entitled ‘‘Measurements of the
Inhibition of Synaptic Activity (MISA)
to Detect, Study and Evaluate All Active
Botulinum Neurotoxin Serotypes,’’ filed
on March 8, 2013. The United States
Government, as represented by the
Secretary of the Army, has rights to this
invention.
SUMMARY:
Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
tkelley on DSK3SPTVN1PROD with NOTICES
ADDRESSES:
For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
16:40 Jan 10, 2014
Jkt 232001
BILLING CODE 3710–08–P
Department of the Army
BILLING CODE 3710–08–P
Notice of Availability for Exclusive,
Non-Exclusive, or Partially-Exclusive
Licensing of an Invention Concerning
Contact Pathway and Tissue Kallikrein
Inhibitors Can Prevent/Reduce
Leakage Caused by Hantavirus
DEPARTMENT OF DEFENSE
Department of the Army
Notice of Availability for Exclusive,
Non-Exclusive, or Partially-Exclusive
Licensing of an Invention Concerning
Low Fat, High Protein, High
Carbohydrate Complete Enteral
Nutritional Compositions for Treatment
of Burn Patients
Department of the Army, DoD.
Notice.
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
733,938, entitled ‘‘Low Fat, High
Protein, High Carbohydrate Complete
Enteral Nutritional Compositions for
Treatment of Burn Patients,’’ filed on
December 6, 2012. The United States
Government, as represented by the
Secretary of the Army, has rights to this
invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to low fat, high
protein, high carbohydrate enteral
nutritional formulations for use in
providing the complete nutritional
needs of subjects with severe burn,
methods of providing nutritional
support to burn patients using these
formulations, and methods of making
the same. These complete enteral
nutritional formulations are polymeric,
concentrated, and do not contain added
arginine. In addition, these enteral
nutritional formulations are
SUMMARY:
Notice of Availability for Exclusive,
Non-Exclusive, or Partially-Exclusive
Licensing of an Invention Concerning
Measurements of the Inhibition of
Synaptic Activity (MISA) To Detect,
Study and Evaluate All Active
Botulinum Neurotoxin Serotypes
[FR Doc. 2014–00287 Filed 1–10–14; 8:45 am]
[FR Doc. 2014–00283 Filed 1–10–14; 8:45 am]
ACTION:
Department of the Army
homogeneous solutions that flow
through tubing well.
The
invention relates to measurements of
spontaneous or evoked electrical
activity in networked populations of
primary neurons or stem cell-derived
neurons as a rapid, sensitive assay for
the presence of functional botulinum
neurotoxin (BoNT) in various matrices.
SUPPLEMENTARY INFORMATION:
AGENCY:
DEPARTMENT OF DEFENSE
2157
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
851,573, entitled ‘‘Contact Pathway and
Tissue Kallikrein Inhibitors can
Prevent/Reduce Leakage Caused by
Hantavirus,’’ filed on March 15, 2013.
The United States Government, as
represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
SUMMARY:
For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to treatment of
vascular leakage symptoms infected
with the Hantavirus using drugs that are
already FDA approved.
FOR FURTHER INFORMATION CONTACT:
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014–00285 Filed 1–10–14; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Defense Acquisition Regulations
System
[Docket Number DARS–2013–0038]
Submission for OMB Review;
Comment Request
ACTION:
E:\FR\FM\13JAN1.SGM
Notice.
13JAN1
]]>Agencies
[Federal Register Volume 79, Number 8 (Monday, January 13, 2014)]
[Notices]
[Pages 2156-2157]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00286]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Notice of Availability for Exclusive, Non-Exclusive, or
Partially-Exclusive Licensing of an Invention Concerning Imidazenil, or
a Combination of Imidazenil and [+]-Huperzine A and/or [-]-Huperzine A
for Protection Against and/or Treatment of Seizure/Status Epilepticus
and Neuropathology Following Nerve Agent or Organophosphate Exposure,
Compositions and Kits
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Announcement is made of the availability for licensing of the
invention set forth in U.S. Provisional Patent Application Serial No.
61/726,753, entitled ``Imidazenil, or a Combination of Imidazenil and
[+]-Huperzine A and/or [-]-Huperzine A for Protection Against and/or
Treatment of Seizure/Status Epilepticus and Neuropathology Following
Nerve Agent or Organophosphate Exposure, Compositions and Kits,'' filed
on November 15, 2012. The United States Government, as represented by
the Secretary of the Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.
[[Page 2157]]
SUPPLEMENTARY INFORMATION: The invention relates to methods,
compositions and kits for use in protection against and/or treatment of
chemical warfare nerve agent (CWNA) and/or organophosphate (OP)
pesticide/insecticide exposure. In particular, the present invention
relates to methods, compositions and kits for treating, preventing,
inhibiting or reducing a seizure, status epilepticus,
neuropathogenesis, or a neuropathology caused by exposure to a CWNA or
an OP pesticide/insecticide using (a) imidazenil, (b) a combination
treatment comprising imidazenil and [+]-Huperzine A, (c) a combination
treatment comprising imidazenil and [-]-Huperzine A, or (d) a
combination treatment comprising imidazenil, [+]-Huperzine A and [-]-
Huperzine A.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014-00286 Filed 1-10-14; 8:45 am]
BILLING CODE 3710-08-P
